CSTL (Castle Biosciences, Inc.) רווח נקי למניה (EPS TTM)

Castle Biosciences develops high-margin oncology tests with excellent scalability potential, although business success relies on coverage by US government insurance. This daily chart from the GURU.Markets platform reflects the trend of net profit per share over the last 12 months, where the -0.77 mark serves as the current indicator. Automated laboratories in Arizona and Texas with strict climate control ensure the stability of the analyses.

Assessing asset reliability begins with analyzing a business's ability to generate real cash flow per share of capital. The trailing twelve months (TTM) net income per share measures final profitability, combining financial efficiency with the ethical approach of Castle Biosciences (CSTL) toward sustainable diagnostics, which allows an investor to determine profit resilience against operating expenses via this chart.